Drug discovery has never moved faster. The tools available to researchers today, from AI-assisted molecular screening to advanced nanotechnology platforms, have dramatically compressed timelines that once took decades. Despite this acceleration, a troubling pattern persists, and that is most innovations developed in the laboratory never reach the patients who actually need them.In this episode of Discovery Loop, host Trisha Pillay sits down with Christian Nkanga, Chief Scientific Officer at Memsel, to examine why the gap between scientific discovery and clinical reality remains so wide. They also covered what the pharmaceutical industry must do differently to close it.Science Is Moving Faster Than the System Can HandleNkanga's perspective on this problem is shaped by more than professional expertise. As both a professor and a practising chief scientist, he has worked directly with diseases for which no adequate treatment exists. That experience gives his analysis a clarity that purely academic commentary rarely achieves. His starting point is a statistic that deserves more attention than it typically receives. Between 2000 and 2019, approximately two million publications were produced on nanotechnology. Of those, roughly 80 products received FDA approval. Two million studies, but only 80 approved products.The science, Nkanga argues, is not the problem. The problem is the system through which that science must travel to reach patients. Regulatory requirements, safety validation, reproducibility standards, manufacturing scale-up, and quality management all stand between a laboratory result and a licensed therapy. Each stage creates another point where promising research can stall. The challenge for pharmaceutical professionals is not to dismiss these requirements. They exist for good reason. The challenge is to understand them early enough to design research programmes that can actually survive contact with them.Documentation, Reproducibility, and the Trust Regulatory Agencies RequireNkanga is equally direct about the internal practices that separate successful development programmes from those that fail to progress. Effective documentation and reproducibility are not bureaucratic obligations. They are the foundation on which regulatory trust is built. Regulatory agencies cannot approve what they cannot verify. When a research team submits data to support a clinical application, the quality of that documentation, its completeness, its consistency, and its internal coherence communicate something essential about the rigour of the science behind it.Teams that treat documentation as an afterthought, to be assembled retrospectively once the scientific work is complete, consistently find themselves unable to satisfy the evidentiary standards that approval requires. Reproducibility carries the same weight. If a result cannot be replicated under defined conditions, it cannot form the basis of a product that will be manufactured at scale and administered to patients. Building reproducibility into research design from the outset, rather than hoping it emerges naturally, is one of the clearest predictors of whether a programme will survive into later development stages.Translational Development as a DisciplineThe broader argument running through this conversation is that translational development, the process of moving science from experimental success to clinical application, needs to be treated as a distinct and rigorous discipline in its own right. It is not a natural extension of good research. It requires a different set of skills, a different set of questions, and a different understanding of what success looks like.For pharmaceutical professionals, that means building translational thinking into programmes from day one. It means asking not only whether a compound works in a controlled setting, but whether the evidence generated is sufficient to persuade a regulator, manufacturable at a viable cost, and relevant to the clinical problem it claims to solve. The patients waiting for those innovations do not have the luxury of waiting for the industry to work this out incrementally. The science is ready. The question is whether the systems, practices, and disciplines needed to translate it are ready too. For more pharmaceutical science and drug discovery insights, visit Memsel or connect with the guest:Christian Nkanga: LinkedIn | Chief Scientific Officer, MemselTakeawaysInnovation in drug discovery is accelerating, but real-world impact is limited.Only a small fraction of scientific knowledge translates into marketable products.Pre-research phases are critical and often underestimated in drug development.Successful programs focus on scalability and reproducibility from the start.Outsourcing non-core functions can help small companies focus on innovation.Good documentation practices are essential for regulatory approval and reproducibility.Engaging end-users early in the process is vital for successful product ...
Show More
Show Less
30 mins